Reviewed by Julian Douwes M.D., Chief Medical Officer, Klinik St. Georg
Killing the pathogen is only half the treatment. Lyme neuroborreliosis disrupts large-scale brain networks, and chronic neuroinflammation can persist long after spirochete clearance. Neurostimulation therapies actively rehabilitate these damaged neural circuits, addressing the brain fog, sensory overload, and autonomic dysfunction that antibiotics and hyperthermia alone cannot resolve.
What it is: A suite of non-invasive brain stimulation therapies — including transcranial pulse stimulation, direct current stimulation, vagus nerve stimulation, neurofeedback, and cranial electrotherapy — that target the specific brain networks disrupted by Lyme neuroborreliosis.
Why it matters: Standard antimicrobial and hyperthermia protocols eliminate the pathogen, but the neuroinflammatory damage to brain connectivity persists. These networks need active rehabilitation, not just time.
Who benefits most: Patients with persistent brain fog, autonomic dysregulation, anxiety, or cognitive impairment despite successful antimicrobial treatment. Also patients with overlapping post-COVID neuroinflammation.
Lyme neuroborreliosis is not simply an infection of the brain. It is a disruption of how the brain communicates with itself. Borrelia burgdorferi crosses the blood-brain barrier, triggers microglial activation, and sets off cytokine cascades that damage the connectivity between large-scale neural networks. Even after the spirochetes are eliminated, the inflammatory damage to these circuits remains.
This is why so many patients report persistent cognitive and neurological symptoms after completing antibiotic courses or hyperthermia protocols. The pathogen may be gone, but the networks it disrupted have not recovered. Standard antibiotics do not repair neural connectivity. Hyperthermia does not retrain disrupted brain circuits. These are problems that require a different class of intervention.
Neurostimulation addresses this gap directly. By delivering targeted energy — ultrasound, electrical current, or magnetic fields — to specific brain regions, these therapies modulate neuronal excitability, reduce neuroinflammation, and promote the re-establishment of healthy network patterns. They are the rehabilitation component of a comprehensive Lyme treatment program.
Our symptom assessment evaluates three key brain networks specifically because these networks are the ones most consistently disrupted by Lyme neuroborreliosis.
The human brain operates through coordinated activity across large-scale networks. Three of these networks are particularly relevant to Lyme patients because they govern the cognitive, sensory, and executive functions most commonly impaired by neuroinflammation.
The Default Mode Network is active during self-referential processing, introspection, and mind-wandering. It is the network that allows you to rest mentally, daydream, and process internal thoughts. When Borrelia-driven neuroinflammation disrupts the DMN, patients experience racing thoughts, rumination, an inability to quiet the mind, and difficulty with self-referential processing. The brain cannot shift into its resting state. Even when you are physically exhausted, your mind will not stop.
The Salience Network acts as the brain's filter, determining which stimuli deserve attention and assigning emotional priority to incoming information. It is what allows you to focus on a conversation in a noisy room or to distinguish between a meaningful signal and background noise. When neuroinflammation disrupts the SN, patients experience sensory overload, hypervigilance, emotional dysregulation, and disproportionate stress responses. Ordinary sensory input becomes overwhelming. Emotional reactions feel out of proportion to the trigger.
The Central Executive Network manages working memory, task switching, planning, and complex decision-making. It is what allows you to hold information in mind while you work with it, to manage multiple tasks, and to execute sequential plans. When the CEN is compromised, patients experience what is commonly described as brain fog: difficulty concentrating, inability to multitask, impaired short-term memory, and problems with planning and organization.
The critical issue is connectivity. In healthy brains, these three networks coordinate seamlessly. The SN determines what is important, the CEN executes the response, and the DMN takes over during rest. In Lyme neuroborreliosis, the inflammatory damage disrupts the switching mechanism between these networks. Patients may find themselves stuck in one network's activation pattern, unable to shift appropriately to another. This is why symptoms like brain fog, sensory overload, and racing thoughts often co-occur.
Step 9 of our symptom assessment evaluates these three networks specifically to help characterize the pattern of neurological involvement in your case.
Understanding why brain network disruption persists after infection clearance requires understanding the neuroinflammatory cascade that Borrelia triggers.
Microglia activation. Borrelia lipoproteins activate microglia, the resident immune cells of the central nervous system. Once activated, microglia release pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-1beta. In chronic infection, microglia can become chronically activated, continuing to produce inflammatory mediators even after the triggering pathogen has been eliminated.
Cytokine cascades in the CNS. The inflammatory cytokines released by activated microglia create a self-sustaining inflammatory environment within the central nervous system. These molecules damage myelin, disrupt synaptic function, impair neurotransmitter signaling, and compromise the integrity of neural circuits. The inflammation feeds itself, independent of the original infection.
Blood-brain barrier disruption. Borrelia burgdorferi has a well-documented capacity to cross the blood-brain barrier. In doing so, it damages the barrier's integrity, allowing peripheral immune cells, inflammatory mediators, and toxins to enter the CNS. This further amplifies neuroinflammation and creates a permissive environment for ongoing neural damage.
Persistent inflammatory loops. This is why symptoms persist after pathogen clearance. The original infection triggers microglial activation and cytokine production. These inflammatory mediators damage neural tissue and disrupt network connectivity. The damaged tissue generates further inflammatory signals. The cycle becomes self-perpetuating, no longer dependent on the presence of live spirochetes.
This mechanism shares significant overlap with post-COVID neuroinflammation, where similar microglial activation and cytokine cascades produce comparable cognitive and neurological symptoms. Patients with both histories may experience compounded neuroinflammatory damage affecting the same brain networks.
Each modality targets neuroinflammation and network dysfunction through a different mechanism. Used in combination and tailored to individual diagnostic findings, they form a comprehensive neurorehabilitation protocol.
TPS delivers focused ultrasound pulses through the skull to stimulate deep brain structures with millimeter precision. Unlike electromagnetic approaches, ultrasound penetrates to subcortical targets that surface-level stimulation cannot reach. This makes TPS particularly valuable for Lyme patients, because the neuroinflammatory damage often extends beyond the cortical surface into deeper brain regions.
TPS can target specific networks — DMN, SN, or CEN — based on the patient's diagnostic mapping. The ultrasound pulses stimulate mechanosensitive ion channels in neurons, modulate microglial activity, and promote neuroplasticity. At Klinik St. Georg, TPS protocols are designed around each patient's quantitative EEG findings, directing stimulation to the networks showing the most significant dysfunction.
Treatment sessions are non-invasive and do not require sedation. A typical protocol involves multiple sessions over the course of the inpatient stay, with effects that continue to consolidate in the weeks following treatment.
tDCS applies low-intensity electrical current (typically 1–2 milliamps) to the scalp through surface electrodes. Depending on electrode placement and polarity, tDCS can either enhance or inhibit activity in targeted cortical regions. Anodal stimulation increases neuronal excitability; cathodal stimulation decreases it.
For Lyme patients, tDCS is primarily used to improve working memory and reduce brain fog by enhancing activity in the dorsolateral prefrontal cortex, a key node of the Central Executive Network. It can also be used to modulate overactive regions contributing to anxiety or sensory overload.
One significant advantage of tDCS is its portability. After an initial clinic-based protocol establishes the correct electrode placement and parameters, patients can continue maintenance sessions at home with a personal device. This makes tDCS a valuable bridge between the intensive inpatient treatment phase and long-term neurorehabilitation.
taVNS stimulates the auricular branch of the vagus nerve through a small electrode placed on the ear. The vagus nerve is the primary conduit of the parasympathetic nervous system and plays a central role in modulating inflammation through the cholinergic anti-inflammatory pathway.
When the vagus nerve is stimulated, it triggers acetylcholine release in the spleen and other immune organs, which suppresses the production of pro-inflammatory cytokines including TNF-alpha. This is not a theoretical mechanism. The cholinergic anti-inflammatory reflex is a well-characterized neuroimmune pathway that directly counteracts the kind of systemic and central inflammation seen in chronic Lyme disease.
taVNS is particularly valuable for patients with autonomic dysregulation, including postural orthostatic tachycardia syndrome (POTS), which is common in chronic Lyme. By restoring vagal tone, taVNS helps rebalance the sympathetic-parasympathetic ratio that becomes skewed toward sympathetic dominance in these patients. Temperature sensitivity, heart rate variability abnormalities, and digestive dysfunction can all improve as vagal tone is restored.
CES delivers microcurrent stimulation (typically less than 1 milliamp) through electrodes placed on the earlobes or behind the ears. The current modulates neurotransmitter activity in the brainstem and limbic system, with documented effects on serotonin, GABA, and endorphin levels.
CES is FDA-cleared for the treatment of anxiety, depression, and insomnia — three of the most common comorbid symptoms in chronic Lyme disease. For patients whose neuropsychiatric symptoms are driven at least in part by neuroinflammation-related neurotransmitter disruption, CES offers a non-pharmacological intervention that can reduce reliance on psychotropic medications.
Like tDCS, CES devices are portable. Patients can continue daily or nightly sessions at home after the inpatient treatment period, supporting long-term symptom management. CES is complementary to the other neurostimulation modalities and is often used in the evening hours during inpatient treatment to support sleep quality.
Neurofeedback is a form of biofeedback in which the patient's brain activity is monitored in real time using electroencephalography (EEG), and the patient is trained to self-regulate their own neural patterns through auditory or visual feedback.
The process begins with quantitative EEG (qEEG) mapping, which creates a detailed topographical map of brain activity across frequency bands. This map reveals exactly where and how brain activity deviates from healthy patterns. In Lyme patients, common findings include excess theta activity (associated with brain fog), reduced alpha power (associated with difficulty relaxing), and disrupted coherence between brain regions (reflecting impaired network connectivity).
Based on the qEEG findings, a personalized neurofeedback protocol trains the patient to normalize these patterns. The brain learns, through operant conditioning, to produce healthier activity patterns. Over multiple sessions, these changes consolidate and become the brain's new default. Neurofeedback is particularly effective for the DMN-SN-CEN imbalance seen in neuro-Lyme, because it directly trains the switching mechanism between these networks.
EMTT delivers high-energy magnetic field pulses at frequencies between 100 and 300 kHz, penetrating up to 12 centimeters into tissue. Originally developed for musculoskeletal applications, EMTT is an emerging modality in neurological rehabilitation, where its capacity to modulate cellular metabolism and reduce inflammation shows promise for patients with neuroinflammatory conditions.
For Lyme patients, EMTT offers a dual benefit. Many patients present with both neurological symptoms and musculoskeletal pain from Borrelia involvement in joints and connective tissue. EMTT can address both domains in a single session. Its role in neurological rehabilitation for Lyme disease is still being characterized, but early clinical observations suggest it may support neural tissue recovery and reduce localized neuroinflammation.
Neurostimulation does not replace hyperthermia or antimicrobial therapy. It complements them. The treatment rationale is straightforward: hyperthermia and targeted antimicrobials eliminate the pathogen. Neurostimulation rehabilitates the brain networks that the pathogen damaged.
In the treatment sequence at Klinik St. Georg, neurostimulation typically begins during or after the antibiotic-augmented thermotherapy (AAT) course. The timing is deliberate. As the infectious burden is reduced and the source of ongoing neuroinflammation is removed, neurostimulation can work more effectively to restore healthy network patterns without the interference of active infection.
Treating the infection is necessary. Restoring the brain is equally important. A treatment program that addresses only one of these dimensions leaves a significant component of the disease untreated. Many patients who report only partial improvement after hyperthermia are experiencing exactly this: the infection has been addressed, but the neural damage has not.
Neurostimulation is most commonly appropriate for patients who:
Not every patient requires neurostimulation. Some patients recover full cognitive and neurological function through pathogen-directed treatment alone. The determination is made based on clinical assessment, symptom profile, and where applicable, quantitative EEG findings. If neurostimulation is not indicated in your case, your medical team will tell you that directly.
The pathogen-directed cornerstone of the protocol. Controlled therapeutic fever targets Borrelia at temperatures where it becomes structurally unstable.
How hyperthermia, antimicrobials, apheresis, immune modulation, and detoxification work together in one coordinated multimodal treatment program.
Blood filtration that removes inflammatory mediators and immune complexes, reducing the chronic inflammatory burden that perpetuates neurological symptoms.
The assessment screens for disruption across the Default Mode, Salience, and Central Executive Networks. Understanding your neurological profile is the first step toward a targeted treatment plan.
Take the symptom assessment